Home > Companies > Thought Leaders > Q&A with Fredrik Sundberg, Global Director Strategic Customer Relations at Cytiva

Q&A with Fredrik Sundberg, Global Director Strategic Customer Relations at Cytiva

Media 7 | September 17, 2021

Fredrik Sundberg, Global Director Strategic Customer Relations at Cytiva, is responsible for working with the pharmaceutical industry to improve current workflows with innovative bioanalytical solutions. He also advises on R&D projects and business development activities. Fredrik is the author of several publications on drug discovery and biosimilar strategies. He is also a member of an EMEA Pharmaceutical Industry Expert Panel, and he lectures and discusses regulatory issues with government officials and health authorities.

It is important to view drug discovery and development projects as long-term strategic activities. You could say, it is more like a marathon than a sprint.



MEDIA 7: Could you please take us through your professional journey?
FREDRIK SUNDBERG: I am currently based at Cytiva HQ in Uppsala, Sweden, working as the Company’s subject matter expert in bioprocess market trends, analytics, and regulatory. As the Global Director of Strategic Customer Relations and Technology at Cytiva, I am responsible for working with the biopharmaceutical industry to improve current workflows with innovative methodologies and analytical solutions including validation strategies. Apart from that, I also advise on R&D projects and business development activities. Since joining the solution-provider business in 1998, I have had different roles within senior product management and strategic marketing as well as the executive commercial leadership team. For the past several years, I have been leading a Global Expert Team initiative focused on application support through strategic customer collaborations to deliver impactful outcomes with novel analytical solutions to improve drug discovery and bioprocessing operations.

Prior to Cytiva, I had various project management roles in Pfizer’s Process Development and Bio-analysis groups, where I gained extensive experience in commercial manufacturing, continuous improvement projects (Kaizen), clinical trials, and capital investment projects. Regulatory compliance has always been near and dear to my heart. I started working actively with health authorities globally already in 1995 and hold a track record including hundreds of successfully executed equipment qualification projects, plus dozens of health authority approved assays to support development programs including GMP manufacturing of commercial drugs.


M7: Cytiva recently opened a new experience and learning lab in Singapore. How will this new lab contribute to the country’s biopharma ecosystem?
FS: Our Cytiva Experience Learning Lab (CELL) in Singapore, established in April 2021, is an educational facility that provides access to application training in specialized bioprocessing techniques. We opened the lab in Singapore to strengthen the country’s local biopharma ecosystem and it will contribute to Singapore’s goal to be more innovative and competitive in the biopharmaceutical industry. It is also part of our expansion plans to meet the increasing demands in the region. The lab will be equipped with the latest process equipment, research tools, and digital technologies. It can provide hands-on training and know-how to both researchers and bio-manufacturers, supporting them, and bringing their innovation through development and to market more efficiently. In addition, the lab will serve as a platform for the exchange of important ideas and access to the latest technology. We will also support talent development as there is a shortage of well-trained staff in bioprocessing globally. In Singapore, we aim to be a key partner and enabler to support their ambition to be a leading economy of technology and innovation. Our expertise will make sure to facilitate the development of local R&D and digital manufacturing talent in Singapore.


In general, there are increasing demands to deliver drugs to the market faster.



M7: What are the top challenges that you see for the industry this year?
FS: Major challenges are complex modalities, process economics, lack of trained staff, harmonization of regulatory requirements, and validation standardization. Biologics continue to go strong, but more complex modalities, such as ADCs, bi-specifics, fragments, viral vectors, etc. are increasing. New modalities require technology innovation for efficient manufacture as there are no platforms available and establishing well-characterized biological products is becoming increasingly difficult. Biosimilars are steadily increasing, here analytics really take center stage as it is very challenging to establish bio-similarity and navigate through the regulatory maze.

There is an increasingly competitive landscape with a focus on reducing COGS and accelerating time-to-market. It is challenging to optimize productivity without compromising on quality. In general, there are increasing demands to deliver drugs to the market faster. For example, COVID-19 vaccines and drugs dominated the industry in 2020. Here speedy delivery to market, security-of-supply, and innovation will continue to be critical. Manufacturing capacity is another bottleneck and there are issues around sustainability. The overall cost-pressure and need-for-speed will drive both process intensification and process analytical technology implementation, such as in-line or on-line biosensors. Digital solutions and automation are overall drivers for future efficiency, but cyber-security will continue to be a challenge together with associated complex validation issues for computerized systems.


M7: How do you maintain strong, mutual partnerships with academic and pharmaceutical customers?
FS: By taking a true customer-and application-centric approach to address the current challenges in biopharma development and manufacturing. It is important to view drug discovery and development projects as long-term strategic activities. You could say, it is more like a marathon than a sprint. It is important to work as long-term partners and make sure to address the most pressing challenges in the best possible way. For example, when deciding upon analytical control strategy, always focus on the critical quality attributes of the customer’s drug molecule and then pick the best fit-for-purpose methods. Do not fall into the trap of “we’ll just keep on doing what we’ve always done”. It is very important to have an open mind and a thorough understanding of the client’s process and strategic objectives. This is where our decades of expertise play a key role together with our unique way of working as a true partner.


Drug pipelines are now more diverse than ever, which will require new technology and more flexibility.



M7: How are biopharma companies’ needs and values changing? How will these changes affect the decision-making process?
FS: The industry is undergoing unprecedented change with biologics going off-patent and new treatments emerging. Drug pipelines are now more diverse than ever, which will require new technology and more flexibility. There is also a shift to local manufacturing, fueled by COVID-19 developments, which have set new standards for collaborations between academic power centers, global biopharma outfits, vendor companies, and regulators to accelerate speed to market. This puts pressure on the supply chain and security of supply. We are now expected to move faster but still meet compliance expectations. What do these changes really mean for the biopharma industry? Well, companies need to be able to develop new drugs at lower costs through process intensification and innovation, have more flexibility and adapt quickly to market changes, and be able to move from idea-to-product with entirely new levels of speed and efficiency. We’re now not only talking time-to-result but really time-to-decision. Solution-providers will need to adapt and make sure to evolve along with these market trends, customer needs, and new expectations.


M7:  If we were talking a year from now celebrating what a great 12 months it’s been for you in this role, what would you have achieved?
FS: My mission is to advance therapeutics and vaccines development. From that perspective, I wish to keep on channeling my 25+ years of experience towards strategic partnerships with customers to focus on innovative bioprocessing solutions and enable better characterization of complex biologics to support their development efforts of novel drugs for indications with unmet needs. Additionally, together with other key opinion leaders and health authorities, implement a globally recognized validation pathway for assays to accelerate comparability assessment and release testing.

ABOUT CYTIVA

Cytiva is a global provider of technologies and services that advance and accelerate the development and manufacture of therapeutics. As a trusted partner to customers that range in scale and scope, Cytiva brings speed, efficiency, and capacity to research and manufacturing workflows, enabling the development, manufacture, and delivery of transformative medicines to patients. We are 7000+ associates with operations in 40 countries. Our customers are working with fundamental biological research to life-saving vaccines, biological drugs, and novel cell and gene therapies.

More THOUGHT LEADERS

Botco.ai's Co-Founder & Executive Chairman, Anu Shukla says, 'Instant' is the new mantra

Media 7 | November 15, 2021

Anu Shukla, Co- Founder & Executive Chairman at Botco.ai explores the latest features on Botco.ai 2.0 and how it helps marketers in health and wellness verticals make more personalized, analytical and actionable insight-driven campaigns. Read on to find out about the biggest challenges in the current COVID-19 influenced product marketing landscape....

Read More

Q&A with Cecil Nick, Vice President at Parexel

Media 7 | August 2, 2021

Cecil Nick, Vice President (Biotechnology) at Parexel, is a biochemistry graduate and regulatory professional with over 30 years experience specializing in the clinical development of biological and biotech products. He has supported 7 biosimilar marketing approvals and has over 80 biosimilar Agency interactions in EU, US, Canada and RoW. He offers extensive expertise to clients with respect to biosimilars, comparabilty, clinical development, orphan drugs and training. He is a fellow of TOPRA and has been a guest lecture at Cardiff University for MSc in Clinical Research, and Greenwich University for MSc in Pharmaceutical Sciences, courses and Biotech Module leader for the TOPRA MSc course. He was on the editorial panel of SCRIP Clinical Research and has over 30 publications to his name....

Read More

Q&A with Craig Misrach, President and Board Member at UpLyft

Media 7 | December 8, 2020

Craig Misrach, President and Board Member at UpLyft joined the organization in 2018, spearheading the company's product launch and commercialization efforts. He began his career at Deloitte where he audited various lower middle-market businesses as a Senior Accountant. Maintaining an active Certified Public Accountant (CPA) license, Mr. Misrach serves on the Board of Directors of Aculief and the Jewish Community Foundation, San Diego. MEDIA 7: Could you tell us about your career journey from Deloitte to UpLyft? CRAIG MISRACH: I started my career at Deloitte as a public accountant and auditor just trying to get the work experience necessary to obtain my CPA license in the State of California. Little did I know how working in janitor closets at client’s office locations whereby doing your job entailed asking questions and information requests from people who didn’t want to talk to you could build so much character! I left Deloitte to join my client Silvergate Bank where I was the Controller in charge of managing ~$500M in assets at the age of 25. Not only did I gain management responsibility at Silvergate overseeing and working with a staff of 9 individuals, but I also was able to observe first-hand what it was like working in a fast-paced growing entrepreneurial culture as we grew from ~20 to ~70 employees in a short two year period. I decided to go obtain my MBA at the University of Virginia to round out my skill sets and start a new business from the ground up. This was not a traditional path to do so at the time as most graduate students would go get their MBA from a top-tier program to become an investment banker, management consultant, or marketing manager at a Fortune 500 company. I knew from the time early in my career, and in watching my father start his own real estate business growing up in Ohio, that with hard work and perseverance I could start a successful business from the ground up. I started my first venture, Freedom Meditech, by way of learning about the diabetes field in my MBA program and researching the reasons why it was still status quo (not just in 2006 but also still today 15 years later) for people with diabetes to be pricking their finger to determine their blood glucose information. I thought that was so archaic and not fair to such individuals when there was better technology available (subject to FDA compliance) to obtain this information non-invasively. I spent 8+ years as the Founding CEO of Freedom Meditech, where under my leadership, we became the 1st company in the world to obtain FDA clearance for a non-invasive diabetes diagnostic test. The test worked by shining light in a person’s eye for 6 seconds. It was truly revolutionary and the FDA clearance we obtained (the first in the world – we estimated $1B of venture capital went into failed attempts of companies to obtain this FDA clearance and commercialize) was likely one the proudest moments in my career because it was a team effort and a culmination of hard work, numerous late nights, and extremely tough decisions along the way of reducing to practice a prototype, conducting clinical studies, analyzing data, and performing this process all over again several times to support our FDA submission. We built an entire sales organization, international distribution network, sold millions of dollars of product around the world, and then eventually sold the business to Sinocare LTD in China. Our product (ClearPath DS-120) is still used to this day to early detect diabetes and pre-diabetes in patients by clinicians all over the world. The past 5 years I have spent “giving back” to entrepreneurs and the community by way of participating on Boards of Directors and mentoring aspiring entrepreneurs. This includes positions I have held as a board member on Aculief (sold – June 2020), as a Business/Finance mentor for the San Diego Sports Innovation network, and as a Board Member for the Jewish Community Foundation in San Diego. I was introduced to UpLyft and our Founder in 2018. I was skeptical at first of the product mostly because I was not familiar with the field and I did not have a frame of reference for how “unique” UpLyft was or the value proposition it embodied. With an investor mentality, I performed due diligence on the durable medical equipment (DME) landscape, other “lifts” on the market for transferring individuals from bedside to wheelchair, and the size of the market opportunity in the US and around the world. Additionally, I had the benefit of being introduced to the company by my contract manufacturer at my last venture (who was slated to be the contract manufacturer for UpLyft), and that helped gain the confidence that we could manufacture UpLyft with impeccable quality, reasonable cost basis, and in a reasonable timeline. I then signed on to be UpLyft’s President and CEO and since that time we have raised capital, performed extensive customer validation (both for the direct to consumer home market and the for the institutional healthcare facility marketplace), accepted pre-orders from customers, and now are staging the business and technology for mass manufacturing in an FDA-compliant manner. M7:  UpLyft is the world’s first Self Transfer System from bed to wheelchair for people with limited mobility. What are the challenges you faced to launch a high-tech innovation like this? CM: Just like any pre-revenue medical device venture, capitalization is key, and you need to kiss a lot of frogs to obtain the capital necessary to invest in manufacturing so you can mass scale your product. Some refer to this as the valley of death. Initially, we were getting lots of questions on customer validation. Things like “the data suggests this will be a huge success, but we have no proof that customers will be this.” Accordingly, we embarked on several initiatives including: 1. Circulation of surveys to potential customers (and family members, caregivers, and healthcare facility workers) to ascertain what was most important from a product feature, utility, and pricing perspective. Check out our B2B Healthcare Facilities for Nurses/Caregivers. 2. Providing in-person demonstrations where we captured testimonials of use and purchase interest. 3. Creating video content of UpLyft in use (seeing is believing). 4. After securing some angel capital that we could devote to efforts outside of R&D prototype creation and patent filing costs, we were able to establish a digital footprint in 2020 (website, order taking capability, e-mail outreach, social media utility, and engagement) whereby actual customer interest could be measured via open pre-order commitments. With this customer validation now in hand, we believe we can be successful in obtaining the necessary capital (and reducing financing risk) to commence manufacturing and finally provide our pre-order customers and other potential customers a delivery date certain so they have the confidence to place a deposit with us and manufacture and deliver products to them. ...

Read More

Botco.ai's Co-Founder & Executive Chairman, Anu Shukla says, 'Instant' is the new mantra

Media 7 | November 15, 2021

Anu Shukla, Co- Founder & Executive Chairman at Botco.ai explores the latest features on Botco.ai 2.0 and how it helps marketers in health and wellness verticals make more personalized, analytical and actionable insight-driven campaigns. Read on to find out about the biggest challenges in the current COVID-19 influenced product marketing landscape....

Read More

Q&A with Cecil Nick, Vice President at Parexel

Media 7 | August 2, 2021

Cecil Nick, Vice President (Biotechnology) at Parexel, is a biochemistry graduate and regulatory professional with over 30 years experience specializing in the clinical development of biological and biotech products. He has supported 7 biosimilar marketing approvals and has over 80 biosimilar Agency interactions in EU, US, Canada and RoW. He offers extensive expertise to clients with respect to biosimilars, comparabilty, clinical development, orphan drugs and training. He is a fellow of TOPRA and has been a guest lecture at Cardiff University for MSc in Clinical Research, and Greenwich University for MSc in Pharmaceutical Sciences, courses and Biotech Module leader for the TOPRA MSc course. He was on the editorial panel of SCRIP Clinical Research and has over 30 publications to his name....

Read More

Q&A with Craig Misrach, President and Board Member at UpLyft

Media 7 | December 8, 2020

Craig Misrach, President and Board Member at UpLyft joined the organization in 2018, spearheading the company's product launch and commercialization efforts. He began his career at Deloitte where he audited various lower middle-market businesses as a Senior Accountant. Maintaining an active Certified Public Accountant (CPA) license, Mr. Misrach serves on the Board of Directors of Aculief and the Jewish Community Foundation, San Diego. MEDIA 7: Could you tell us about your career journey from Deloitte to UpLyft? CRAIG MISRACH: I started my career at Deloitte as a public accountant and auditor just trying to get the work experience necessary to obtain my CPA license in the State of California. Little did I know how working in janitor closets at client’s office locations whereby doing your job entailed asking questions and information requests from people who didn’t want to talk to you could build so much character! I left Deloitte to join my client Silvergate Bank where I was the Controller in charge of managing ~$500M in assets at the age of 25. Not only did I gain management responsibility at Silvergate overseeing and working with a staff of 9 individuals, but I also was able to observe first-hand what it was like working in a fast-paced growing entrepreneurial culture as we grew from ~20 to ~70 employees in a short two year period. I decided to go obtain my MBA at the University of Virginia to round out my skill sets and start a new business from the ground up. This was not a traditional path to do so at the time as most graduate students would go get their MBA from a top-tier program to become an investment banker, management consultant, or marketing manager at a Fortune 500 company. I knew from the time early in my career, and in watching my father start his own real estate business growing up in Ohio, that with hard work and perseverance I could start a successful business from the ground up. I started my first venture, Freedom Meditech, by way of learning about the diabetes field in my MBA program and researching the reasons why it was still status quo (not just in 2006 but also still today 15 years later) for people with diabetes to be pricking their finger to determine their blood glucose information. I thought that was so archaic and not fair to such individuals when there was better technology available (subject to FDA compliance) to obtain this information non-invasively. I spent 8+ years as the Founding CEO of Freedom Meditech, where under my leadership, we became the 1st company in the world to obtain FDA clearance for a non-invasive diabetes diagnostic test. The test worked by shining light in a person’s eye for 6 seconds. It was truly revolutionary and the FDA clearance we obtained (the first in the world – we estimated $1B of venture capital went into failed attempts of companies to obtain this FDA clearance and commercialize) was likely one the proudest moments in my career because it was a team effort and a culmination of hard work, numerous late nights, and extremely tough decisions along the way of reducing to practice a prototype, conducting clinical studies, analyzing data, and performing this process all over again several times to support our FDA submission. We built an entire sales organization, international distribution network, sold millions of dollars of product around the world, and then eventually sold the business to Sinocare LTD in China. Our product (ClearPath DS-120) is still used to this day to early detect diabetes and pre-diabetes in patients by clinicians all over the world. The past 5 years I have spent “giving back” to entrepreneurs and the community by way of participating on Boards of Directors and mentoring aspiring entrepreneurs. This includes positions I have held as a board member on Aculief (sold – June 2020), as a Business/Finance mentor for the San Diego Sports Innovation network, and as a Board Member for the Jewish Community Foundation in San Diego. I was introduced to UpLyft and our Founder in 2018. I was skeptical at first of the product mostly because I was not familiar with the field and I did not have a frame of reference for how “unique” UpLyft was or the value proposition it embodied. With an investor mentality, I performed due diligence on the durable medical equipment (DME) landscape, other “lifts” on the market for transferring individuals from bedside to wheelchair, and the size of the market opportunity in the US and around the world. Additionally, I had the benefit of being introduced to the company by my contract manufacturer at my last venture (who was slated to be the contract manufacturer for UpLyft), and that helped gain the confidence that we could manufacture UpLyft with impeccable quality, reasonable cost basis, and in a reasonable timeline. I then signed on to be UpLyft’s President and CEO and since that time we have raised capital, performed extensive customer validation (both for the direct to consumer home market and the for the institutional healthcare facility marketplace), accepted pre-orders from customers, and now are staging the business and technology for mass manufacturing in an FDA-compliant manner. M7:  UpLyft is the world’s first Self Transfer System from bed to wheelchair for people with limited mobility. What are the challenges you faced to launch a high-tech innovation like this? CM: Just like any pre-revenue medical device venture, capitalization is key, and you need to kiss a lot of frogs to obtain the capital necessary to invest in manufacturing so you can mass scale your product. Some refer to this as the valley of death. Initially, we were getting lots of questions on customer validation. Things like “the data suggests this will be a huge success, but we have no proof that customers will be this.” Accordingly, we embarked on several initiatives including: 1. Circulation of surveys to potential customers (and family members, caregivers, and healthcare facility workers) to ascertain what was most important from a product feature, utility, and pricing perspective. Check out our B2B Healthcare Facilities for Nurses/Caregivers. 2. Providing in-person demonstrations where we captured testimonials of use and purchase interest. 3. Creating video content of UpLyft in use (seeing is believing). 4. After securing some angel capital that we could devote to efforts outside of R&D prototype creation and patent filing costs, we were able to establish a digital footprint in 2020 (website, order taking capability, e-mail outreach, social media utility, and engagement) whereby actual customer interest could be measured via open pre-order commitments. With this customer validation now in hand, we believe we can be successful in obtaining the necessary capital (and reducing financing risk) to commence manufacturing and finally provide our pre-order customers and other potential customers a delivery date certain so they have the confidence to place a deposit with us and manufacture and deliver products to them. ...

Read More

Related News

HEALTH TECHNOLOGY, MEDICAL DEVICES

LMHS, InVita, Lifeline Launch iReferral to Boost Ohio Donation and Transplantation

Licking Memorial Health Systems (LMHS) | January 31, 2023

On January 30, 2023, Licking Memorial Health Systems (LMHS) integrated with Lifeline of Ohio and InVita Healthcare Technologies to launch iReferral to automate its identification and Lifeline's electronic referral of tissue, organ, and eye donors. iReferral will automatically recognize suitable donors and trace the referral process from a hospital to the organ procurement organization (OPO). Apart from gathering information on workflow, nursing time, and returns providers, it will increase opportunities for transplantation and donation, adhering to the federal government's rules. With over 100,000 patients on the nation's waiting list for a life-saving organ transplant, CMS laws require hospitals to direct all potential organ and tissue donors to their federally designated OPO. LMHS Vice President of Acute Care Services, Heather Burkhart, said, "Our staff is constantly looking for ways to enhance the high level of care provided to our patients. The automation offered through iReferral expedites the donor referral process allowing our healthcare providers to spend more time with the patient and their family during the most stressful of times while securing positive outcomes for transplant recipients." (Source – Cision PR Newswire) LMHS President and CEO Rob Montagnese said, "The new system furthers LMHS' efforts to integrate technology that directly impacts patient care while also providing the gift of life to the more than 3,100 people across the state that are waiting for organ, tissue, and eye donations". (Source – Cision PR Newswire) President and CEO of InVita Healthcare Technologies, Todd Collins, expressed, "Congratulations to LMHS and Lifeline of Ohio on their iReferral launch. This successful collaboration deploys scalable technology that helps shift nursing and provider resources back to patient care and provides greater access to life-saving gifts for the many in need by ensuring the critical first step of the intricate donation process is streamlined and made more reliable." (Source – Cision PR Newswire) About Licking Memorial Health Systems (LMHS) LMHS is a non-profit healthcare organization that consists of Licking Memorial Hospital, a physician corporation, and the Licking Memorial Health Foundation. Licking Memorial Health Foundation is funding and developing resources for LMHS. It utilizes the best technology to help patients and visitors with their safety and healthcare requirements. Founded in 1898, it has its headquarters in Newark (Ohio). Licking Memorial Development Council, a committee of business leaders in Licking County, supports LMH Foundation.

Read More

HEALTH TECHNOLOGY, DIGITAL HEALTHCARE

Aluna and ModuleMD Provide Remote Patient Monitoring to Respiratory Patients

Aluna | February 07, 2023

Aluna, an award-winning linked care platform and at-home spirometer, and ModuleMD, an ONC-certified EHR, announced a partnership on February 6, 2023, to give more patients and providers access to the latest lung health technology. Asthma and cystic fibrosis patients can now effortlessly share their daily lung health variations with their doctor, improving results and reducing attacks through earlier and more frequent interventions. This cooperation will enable easy exchange between physicians, payers, and patients on the Aluna RPM care management platform, with all details incorporated into ModuleMD providers' workflow. Charvi Shetty, Founder and CEO of Aluna, stated, "Close monitoring of asthma and other lung conditions is correlated with better patient outcomes." "Providers seeking to provide the highest quality care with Aluna can do so efficiently and profitably for their practice, now fully integrated with ModuleMD," she added. (Source – Cision PR Newswire) Abhinay Rao, CEO of ModuleMD, remarked, "This partnership represents an important shift in the way clinicians provide patient centered care. For true efficiency, everything needs to be connected to the system of record." He added, "At ModuleMD, our mission is to lead innovation in allergy and pulmonology technology. Through this integration with Aluna, medical practices now have a seamless RPM experience to deliver comprehensive care to patients." (Source – Cision PR Newswire) About Aluna Aluna, a digital spirometry platform certified for use by FDA, gives asthma sufferers and their doctors the ability to monitor their lung function in real-time remotely. The Aluna platform allows practices to offer improved medical care to their patients while simultaneously generating an additional revenue stream through reimbursements for remote patient monitoring (RPM).

Read More

FUTURE OF HEALTHCARE, MEDICAL DEVICES

AnMed Chooses XSOLIS' AI for Utilization Management in Its Hospital System

XSOLIS | February 01, 2023

On January 31, 2023, AnMed has chosen XSOLIS, the artificial intelligence company supporting healthcare systems, to remodel its utilization management across its health systems. The XSOLIS' CORTEX platform will share real-time clinical data across its connected network of providers and players. Due to the shortage of nursing staff and increased number of patients, a technology solution would provide accurate patient status from the beginning to minimize rejections and associated interactions with payers. XSOLIS will centralize AnMed's operations, track work over its three hospitals, and connect its Physician Advisor and Utilization Management teams. In addition, CORTEX's advanced case management analytics and reporting efficiencies with AnMed's electronic medical record system will enhance the leverage time of the hospital systems. Associate Vice President of Population Health at AnMed, Suzanne Wilson, said, "When evaluating next-generation utilization management platforms, XSOLIS was in a league of its own. The healthcare industry has reached a tipping point, where improved provider-payer relations are imperative to reduce administrative waste and unnecessary friction. XSOLIS will help us achieve just that through its innovative technology." (Source – Cision PR Newswire) Chief Financial Officer at AnMed, Christine Pearson, said, "This is a challenging time for provider organizations across the U.S. By providing an automated, objective view of medical necessity, XSOLIS will help increase the efficiency of our existing staff so that we can better serve our patients." (Source – Cision PR Newswire) CEO and Co-Founder at XSOLIS, Joan Butters, said, "There is a growing need for transformative solutions as providers continue to contend with a shortage of healthcare professionals and friction across the healthcare system. We're looking forward to helping AnMed transform their operations to work more efficiently internally, as well as with payer organizations." (Source – Cision PR Newswire) About XSOLIS XSOLIS, the technology solutions and data science platform, serves hospitals and payer organizations nationwide for effective healthcare systemization, enhancing data-driven decision-making and collaboration with providers and payers. Its CORTEX, an AI platform, uses real-time predictive analytics to continuously objectify medical needs and care with appropriate settings. In addition, it offers patient status evaluation through health systems, reduces the administrative burden of hospitals, and increases automation between payers, health plans, and providers-sponsored health plans (PSHPs), inpatient as well as observation status. About AnMed AnMed, a non-profitable health system upstate in northeast Georgia and South Carolina, includes four hospital systems: AnMed Cannon in Pickens, AnMed Women's and Children's Hospital, and AnMed Rehabilitation Hospital with around 3,700 employees and 400 physicians. It provides routine care, urgent care as the requirement, life-saving emergency treatment, specialized care, home health visits, and virtual visits, as well as options to schedule an appointment, pay bills, volunteer, access medical records, donate, and find a job in its hospital systems.

Read More

HEALTH TECHNOLOGY, MEDICAL DEVICES

LMHS, InVita, Lifeline Launch iReferral to Boost Ohio Donation and Transplantation

Licking Memorial Health Systems (LMHS) | January 31, 2023

On January 30, 2023, Licking Memorial Health Systems (LMHS) integrated with Lifeline of Ohio and InVita Healthcare Technologies to launch iReferral to automate its identification and Lifeline's electronic referral of tissue, organ, and eye donors. iReferral will automatically recognize suitable donors and trace the referral process from a hospital to the organ procurement organization (OPO). Apart from gathering information on workflow, nursing time, and returns providers, it will increase opportunities for transplantation and donation, adhering to the federal government's rules. With over 100,000 patients on the nation's waiting list for a life-saving organ transplant, CMS laws require hospitals to direct all potential organ and tissue donors to their federally designated OPO. LMHS Vice President of Acute Care Services, Heather Burkhart, said, "Our staff is constantly looking for ways to enhance the high level of care provided to our patients. The automation offered through iReferral expedites the donor referral process allowing our healthcare providers to spend more time with the patient and their family during the most stressful of times while securing positive outcomes for transplant recipients." (Source – Cision PR Newswire) LMHS President and CEO Rob Montagnese said, "The new system furthers LMHS' efforts to integrate technology that directly impacts patient care while also providing the gift of life to the more than 3,100 people across the state that are waiting for organ, tissue, and eye donations". (Source – Cision PR Newswire) President and CEO of InVita Healthcare Technologies, Todd Collins, expressed, "Congratulations to LMHS and Lifeline of Ohio on their iReferral launch. This successful collaboration deploys scalable technology that helps shift nursing and provider resources back to patient care and provides greater access to life-saving gifts for the many in need by ensuring the critical first step of the intricate donation process is streamlined and made more reliable." (Source – Cision PR Newswire) About Licking Memorial Health Systems (LMHS) LMHS is a non-profit healthcare organization that consists of Licking Memorial Hospital, a physician corporation, and the Licking Memorial Health Foundation. Licking Memorial Health Foundation is funding and developing resources for LMHS. It utilizes the best technology to help patients and visitors with their safety and healthcare requirements. Founded in 1898, it has its headquarters in Newark (Ohio). Licking Memorial Development Council, a committee of business leaders in Licking County, supports LMH Foundation.

Read More

HEALTH TECHNOLOGY, DIGITAL HEALTHCARE

Aluna and ModuleMD Provide Remote Patient Monitoring to Respiratory Patients

Aluna | February 07, 2023

Aluna, an award-winning linked care platform and at-home spirometer, and ModuleMD, an ONC-certified EHR, announced a partnership on February 6, 2023, to give more patients and providers access to the latest lung health technology. Asthma and cystic fibrosis patients can now effortlessly share their daily lung health variations with their doctor, improving results and reducing attacks through earlier and more frequent interventions. This cooperation will enable easy exchange between physicians, payers, and patients on the Aluna RPM care management platform, with all details incorporated into ModuleMD providers' workflow. Charvi Shetty, Founder and CEO of Aluna, stated, "Close monitoring of asthma and other lung conditions is correlated with better patient outcomes." "Providers seeking to provide the highest quality care with Aluna can do so efficiently and profitably for their practice, now fully integrated with ModuleMD," she added. (Source – Cision PR Newswire) Abhinay Rao, CEO of ModuleMD, remarked, "This partnership represents an important shift in the way clinicians provide patient centered care. For true efficiency, everything needs to be connected to the system of record." He added, "At ModuleMD, our mission is to lead innovation in allergy and pulmonology technology. Through this integration with Aluna, medical practices now have a seamless RPM experience to deliver comprehensive care to patients." (Source – Cision PR Newswire) About Aluna Aluna, a digital spirometry platform certified for use by FDA, gives asthma sufferers and their doctors the ability to monitor their lung function in real-time remotely. The Aluna platform allows practices to offer improved medical care to their patients while simultaneously generating an additional revenue stream through reimbursements for remote patient monitoring (RPM).

Read More

FUTURE OF HEALTHCARE, MEDICAL DEVICES

AnMed Chooses XSOLIS' AI for Utilization Management in Its Hospital System

XSOLIS | February 01, 2023

On January 31, 2023, AnMed has chosen XSOLIS, the artificial intelligence company supporting healthcare systems, to remodel its utilization management across its health systems. The XSOLIS' CORTEX platform will share real-time clinical data across its connected network of providers and players. Due to the shortage of nursing staff and increased number of patients, a technology solution would provide accurate patient status from the beginning to minimize rejections and associated interactions with payers. XSOLIS will centralize AnMed's operations, track work over its three hospitals, and connect its Physician Advisor and Utilization Management teams. In addition, CORTEX's advanced case management analytics and reporting efficiencies with AnMed's electronic medical record system will enhance the leverage time of the hospital systems. Associate Vice President of Population Health at AnMed, Suzanne Wilson, said, "When evaluating next-generation utilization management platforms, XSOLIS was in a league of its own. The healthcare industry has reached a tipping point, where improved provider-payer relations are imperative to reduce administrative waste and unnecessary friction. XSOLIS will help us achieve just that through its innovative technology." (Source – Cision PR Newswire) Chief Financial Officer at AnMed, Christine Pearson, said, "This is a challenging time for provider organizations across the U.S. By providing an automated, objective view of medical necessity, XSOLIS will help increase the efficiency of our existing staff so that we can better serve our patients." (Source – Cision PR Newswire) CEO and Co-Founder at XSOLIS, Joan Butters, said, "There is a growing need for transformative solutions as providers continue to contend with a shortage of healthcare professionals and friction across the healthcare system. We're looking forward to helping AnMed transform their operations to work more efficiently internally, as well as with payer organizations." (Source – Cision PR Newswire) About XSOLIS XSOLIS, the technology solutions and data science platform, serves hospitals and payer organizations nationwide for effective healthcare systemization, enhancing data-driven decision-making and collaboration with providers and payers. Its CORTEX, an AI platform, uses real-time predictive analytics to continuously objectify medical needs and care with appropriate settings. In addition, it offers patient status evaluation through health systems, reduces the administrative burden of hospitals, and increases automation between payers, health plans, and providers-sponsored health plans (PSHPs), inpatient as well as observation status. About AnMed AnMed, a non-profitable health system upstate in northeast Georgia and South Carolina, includes four hospital systems: AnMed Cannon in Pickens, AnMed Women's and Children's Hospital, and AnMed Rehabilitation Hospital with around 3,700 employees and 400 physicians. It provides routine care, urgent care as the requirement, life-saving emergency treatment, specialized care, home health visits, and virtual visits, as well as options to schedule an appointment, pay bills, volunteer, access medical records, donate, and find a job in its hospital systems.

Read More

Spotlight

Cytiva

Cytiva is a global provider of technologies and services that advance and accelerate the development and manufacture of therapeutics. As a trusted partner to customers that range in scale and scope, Cytiva brings speed, efficiency, and capacity to research and manufacturing workflows, enabling the d...

Events

Resources

resource image

DIGITAL HEALTHCARE, MEDICAL DEVICES

Sunfusion Infusion Pump QC Process Accuracy Calibration

Video

resource image

DIGITAL HEALTHCARE, MEDICAL DEVICES

Vscan Air with Digital Tools

Video

resource image

DIGITAL HEALTHCARE, MEDICAL DEVICES

Sunfusion Infusion Pump QC Process Accuracy Calibration

Video

resource image

DIGITAL HEALTHCARE, MEDICAL DEVICES

Vscan Air with Digital Tools

Video

resource image

DIGITAL HEALTHCARE, MEDICAL DEVICES

Framework For Healthcare Web Design Model That Drives Engagement

Video

Events